Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls

Cell Biology and Toxicology

Volumn 23, Issue 1, 2007, Pages 27-37

  Robert, J ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Anthracyclines; Cancer chemotherapy; Cardiotoxicity; Dexrazoxane; Doxorubicin; Rat isolated perfused heart

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLAVONOID; IDARUBICIN; PACLITAXEL; PIRARUBICIN; RAZOXANE; TAXANE DERIVATIVE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART PERFORMANCE; HEART PERFUSION; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HUMAN; ISOLATED HEART; LONG TERM EXPOSURE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; IDARUBICIN; MICE; MODELS, ANIMAL; PERFUSION; RABBITS; RATS; TAXOIDS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33845600436     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-006-0142-9     Document Type: Conference Paper

References (41)

1. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995;13:2827-34.
2. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005-24.
3. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophos phamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22:4958-65.
4. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol. 2004;31(Supplement 13):161-81.
5. Ferrans VJ, Sanchez JA, Herman EH. Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity. In: Muggia FM, Green MD, Speyer JL, eds. Cancer treatment and the heart. Baltimore: The Johns Hopkins University Press; 1992:89-113.
6. Freyer G, Lortholary A, Delcambre C, et al and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience. Clin Oncol. 2004;16:17-23.
7. Ganzina F. 4′-Epi-doxorubicin, a newanalogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983;10:1-22.
8. Gehl J, Boesgaard M, Paaske T, Jensen BV, Dombernowsky P. Paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol. 1996;23(Supplement 15):35-8.
9. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688-99.
10. Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue - are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992;28A:1670-6.
11. Herman EH, Ferrans V. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol. 1986;16:102-6.
12. Herman EH, Ferrans VJ, Jordan W, Ardalan B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol. 1981;31:85-97.
13. Herman EH, el-Hage AN, Ferrans VJ, Ardalan B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol. 1985;78:202-14.
14. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999;17:2237-43.
15. Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991;42:690-719.
16. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997;24 (Supplement 11):S13-9.
17. Imondi AR, Della Torre P, Mazue G, et al. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res. 1996;56:4200-4.
18. Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974;30:292-304.
19. Julicher RH, Sterrenberg L, Bast A, Riksen RO, Koomen JM, Noordhoek J. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol. 1986;38:277-82.
20. Leandro J, Dyck J, Poppe D, et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 1994;74:1152-6.
21. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994;93:433-7.
22. Lorell BH, Wexler LF, Momomura S, Weinberg E, Apstein CS. The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ Res. 1986;58:653-63.
23. Maehara Y, Sakaguchi Y, Kusumoto T, Kusumoto H, Sugimachi K. 4′-O-tetrahydropyranyl-adriamycin has greater antineoplastic activity than adriamycin in various human tumours in vitro. Anticancer Res. 1989;9:387-9.
24. Maral R, Bourat G, Ducrot R, et al. Toxicologic study and experimental antitumor activity of rubidomycin (13, 057 R.P.). Pathol Biol. 1967;15:903-8.
25. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol. 1999;10:553-60.
26. Plandé J, Platel D, Tariosse L, Robert J. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Lett. 2006;161:37-42.
27. Platel D, Pouna P, Bonoron-Adele S, Robert J. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs. 1999;10:671-6.
28. Platel D, Pouna P, Bonoron-Adele S, Robert J. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Appl Pharmacol. 2000;163:135-40.
29. Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse L, Besse P, Robert J. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol. 1995;35:257-61.
30. Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol. 1996;117:1593-9.
31. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J. 1993;70:499-502.
32. 2. Ann Oncol. 2000;11:1029-33.
33. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405-10.
34. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
35. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy. Pediatrics. 1992;89:942-9.
36. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP. Doxorubicin cardiotoxicity. Cancer Treat Rev. 1982;9:149-64.
37. van Acker SA, Kramer K, Voest EE, et al. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother Pharmacol 1996;38:95-101.
38. van Acker FA, Hulshof JW, Haenen GR, Menge WM, van der Vijgh WJ, Bast A. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic Biol Med. 2001;31:31-7.
39. Van Vleet JF, Ferrans VJ. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res 1980;41:1462-9.
40. Van Vleet JF, Greenwood L, Ferrans VJ, Rebar AH. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res. 1978;39:997-1010.
41. Villani F, Galimberti M, Monti E, et al. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Radic Res Commun. 1990;11:145-51.